Trials / Unknown
UnknownNCT01340495
Proton Radiation Therapy for Invasive Breast Cancer Following Mastectomy
Pilot Study of Proton Radiation Therapy for Invasive Breast Carcinoma Following Mastectomy
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study we are looking at a type of radiation called proton radiation which is known to spare surrounding tissue and organs from radiation. The proton radiation will be delivered using 3D conformal proton radiation or scanned beam/IMPT (Intensity Modulated Proton Radiation Treatment). Proton radiation delivers no dose beyond the region requiring treatment. This may reduce side effects that patients would normally experience with conventional radiation therapy or other means of delivering proton radiation therapy. In this study we are evaluating the effectiveness of using proton radiation delivered to reduce side effects association with radiation treatment.
Detailed description
Proton radiation will be delivered daily for approximately 5 1/2 weeks. Patients will be assessed weekly for any side effects they may be experiencing. Patients will have follow-up visits 4 weeks after proton therapy ends, at 6 months, 12 months, and then every year for up to five years after treatment. Follow-up visits will include a physical examination, radiological imaging (if necessary), echocardiogram, and laboratory tests.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Proton Radiation | 45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2017-04-01
- Completion
- 2022-01-01
- First posted
- 2011-04-22
- Last updated
- 2021-01-05
- Results posted
- 2018-04-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01340495. Inclusion in this directory is not an endorsement.